CN1771911A - Re-dispersible nanometer particle of insoluble medicine and its prepn - Google Patents
Re-dispersible nanometer particle of insoluble medicine and its prepn Download PDFInfo
- Publication number
- CN1771911A CN1771911A CN 200510061510 CN200510061510A CN1771911A CN 1771911 A CN1771911 A CN 1771911A CN 200510061510 CN200510061510 CN 200510061510 CN 200510061510 A CN200510061510 A CN 200510061510A CN 1771911 A CN1771911 A CN 1771911A
- Authority
- CN
- China
- Prior art keywords
- redispersible
- nanometer particle
- protective agent
- insoluble medicine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention provides one kind of re-dispersible nanometer particle powder of insoluble medicine sirolimus and its preparation process. The re-dispersible nanometer medicine particle powder consists of nanometer sirolimus particle 0.6-100 wt%, freeze drying protecting agent 0-99.3 wt% and spray drying protecting agent 0-96.4 wt%, and has average particle size after re-dispersion in water of 1000 nm. The nanometer medicine particle powder is prepared through freeze drying process or spray drying process suitable for industrial production. The preparation process has less coagulation of nanometer particle, and the prepared nanometer medicine particle powder may be used in preparing nanometer solid medicine preparations, including tablet, capsule, granule, etc.
Description
Technical field
The invention belongs to redispersible Nano medication manufacturing method of power, relate to the dry compositions screening and the manufacture method of insoluble drug sirolimus nanoparticle suspension.
Background technology
Developing rapidly of nanosecond science and technology greatly promotes the great discovery and the technological revolution in fields such as biotechnology, information technology, caused the great-leap-forward development of nanometer biotechnology and relevant medicinal industry thereof.With " medicine and therapeutic gene nanometer formulation " is the nano-drug preparation theory and the technology of core, is faced with historical opportunity to develop.
Adopt nanotechnology, can greatly increase the specific surface area of water-insoluble drug, improve the dissolution of medicine in body fluid, thereby significantly improve bioavailability of medicament, reduce individual variation, reduce toxic and side effects." Elan Inc. " company has adopted a kind of technology platform that is called as nanocrystal technology (NanoCrystal technology), with a kind of special grinding technology the particle diameter of medicine is reduced to extremely little scope (diameter≤400nm).The sirolimus nanometer sheet that " Elan Inc. " company adopts this technology to produce, approval and list marketing in calendar year 2001 acquisition U.S. FDA become U.S. FDA first granted " nanometer formulation " since the dawn of human civilization.
The Nano medication powder is the basis that follow-up nano-solid preparation is made.By suitable prescription and Technology, the medicament nano granule suspension is manufactured the Nano medication powder that possesses redispersibility, be the basis that Nano medication is really realized industrialization.
Lyophilization and spray drying technology are that liquid or semi-solid form pharmaceutical dispersions create solid forms medicine common method.In the states of matter transformation process of Nano medication powder, its core is the Nano medication powder for preparing at the medicament nano granule suspension, and the diameter of aspirin particle behind the redispersion must be similar or approaching to dry preceding diameter of aspirin particle.Only in this way, could realize the suitability for industrialized production of nanometer formulation product, safe and effective when guaranteeing clinical practice.
Yet, in the Nano medication powder manufacturing technology field of redispersibility, lack system always and effectively explore and research, also lack its corresponding theory and instruct.The redispersibility of Nano medication powder has become a major issue that restricts the Nano medication industrialization at present.Along with the development of nanometer formulation technology, solve this technical problem more apparent urgent.
" a kind of indissoluble medicament nano granule and preparation method thereof " (number of patent application 200510061371.1) described the preparation of insoluble drug sirolimus nanoparticle suspension; with " solvent diffuse-high pressure breast is even " technology; select suitable nanoparticle protective agent, its medicament nano granule particle diameter is controlled in the 500nm.
Based on the nanoparticle that method for preparing obtains, only rely on nanoparticle coating material (surfactant), be difficult to realize the stability of medicament nano granule.Adopt common lyophilization or spray drying process, but adhesion between the associated particle crystallization and growth cause the disappearance of quick redispersibility.The invention describes and adopt lyophilization or spray drying technology, can keep the original particle diameter of medicament nano granule in manufacturing, and the application that realizes aspects such as quick redispersion characteristic.
Summary of the invention
An object of the present invention is to provide a kind of redispersible nanometer particle of insoluble medicine; form by sirolimus nanoparticle and lyophilization or spray drying protective agent poloxamer 188, mannitol, polyvinylpyrrolidone K30; the weight percentage of sirolimus nanoparticle is 0.6%～100%; protective agent poloxamer 188 0%～99.3%; mannitol 0%～93.8%, polyvinylpyrrolidone K30 0%～40.9%.
Medicament nano granule powder provided by the invention, behind the chance water redispersion, its mean diameter is less than 1000nm, or after meeting the water redispersion, its mean diameter is less than 500nm.
Freezing drying protective agent is selected one or more the mixture in polyvinylpyrrolidone k30, poloxamer, mannitol, sorbitol, lactose, sucrose, glucose, the trehalose for use, and its consumption is 0%～99.3% (w/w) of total solid.
The spray drying protective agent is selected one or more the mixture in polyvinylpyrrolidone k30, poloxamer, mannitol, sorbitol, lactose, sucrose, glucose, the trehalose for use, and its consumption is 0～96.4% (w/w) of total solid.
Freezing drying protective agent consists of poloxamer 188 0%～99.3% (w/w), mannitol 0%～90.0% (w/w), polyvinylpyrrolidone k30 0%～40.9% (w/w).
The spray drying protective agent consists of poloxamer 188 0%～43.0% (w/w), mannitol 0%～93.8% (w/w), polyvinylpyrrolidone k30 0%～27.9% (w/w).
Second purpose of the present invention provides the preparation method of redispersibility nanorize medical solid powder, is achieved through the following technical solutions:
(1) freeze-drying preparation: get the medicament nano granule suspension that obtains according to application number 200510061371.1 disclosed methods; after adding the freezing drying protective agent dissolving; place the lyophilizing dish; liquid level is 2～3cm; put on the flaggy of lyophilization mechanical goods chamber; about 6～7 hours of-45 ℃ of pre-freezes; open water vessel refrigeration switch, finish the back in the pre-freeze insulation and open vacuum pump, when the vacuum reading is reduced to 10 handkerchiefs when following; the goods room temperature that raises gradually is to-5 ℃; be incubated about 24～30 hours, when products temperature and flaggy temperature near the time, continue rising flaggy temperature to about 35 ℃ and be incubated 3 hours; lyophilization is about 34 hours altogether, obtains the Nano medication powder.Medicament nano granule powder through freeze-drying prepares can form medicament nano granule by redispersion in distilled water.
(2) spray drying method for preparation: get the medicament nano granule suspension that obtains according to application number 200510061371.1 disclosed methods; add the dissolving of spray drying protective agent respectively; control spray-dired inlet temperature: 130 ℃; leaving air temp: 85 ℃; material flow: 5ml/min; air velocity 600L/min collects and obtains the Nano medication powder.The medicament nano granule powder that spray-dried method prepares can form medicament nano granule by redispersion in distilled water.
Redispersible medicament nano granule powder provided by the invention can prepare the Nano medication solid preparation, and dosage form is tablet, capsule, granule etc.
This medicament nano granule provided by the invention and redispersible medicament nano granule powder, composition is simple, method is practical reliable.Selected main adjuvant poloxamer 188, mannitol, polyvinylpyrrolidone K30 etc. are common medicinal supplementary material.The medicament nano granule manufacture method adopts solvent diffuse-high pressure newborn even, but suitability for industrialized production.Redispersion medicament nano granule manufacturing method of power adopts lyophilization and spray drying, possesses the industrialization prospect of production.
The present invention is to provide a kind of new indissoluble medicament nano granule suspension lyophilization or spray drying and form, comprise lyophilization or spray drying protective agent composition that the nanoparticle particle is provided, can reduce the cohesion of nanoparticle in lyophilizing or the dried process of spray.The present invention provides simultaneously and has used these protectant concrete grammars.
The specific embodiment
The present invention is further described in conjunction with the embodiments.
Embodiment one: the freeze-drying preparation of medicament nano granule powder
Get the medicament nano granule suspension that obtains according to application number 200510061371.1 disclosed methods; with distilled water diluting or without dilution; add poloxamer 188 dissolvings; place the lyophilizing dish; liquid level is 2～3cm; put on the flaggy of lyophilization mechanical goods chamber, about 6～7 hours of-45 ℃ of pre-freezes are opened water vessel refrigeration switch; finish the back in the pre-freeze insulation and open vacuum pump; reduce to 10 handkerchiefs when following when the vacuum reading, the goods room temperature that raises gradually is incubated about 24～30 hours to-5 ℃; when products temperature and flaggy temperature near the time; continue rising flaggy temperature to about 35 ℃ and be incubated 3 hours, lyophilization is about 34 hours altogether, obtains the Nano medication powder.
Nano medication powder adding distil water is diluted to the preceding same medicine concentration of lyophilizing; hand vibration 1min redispersion; medicament nano granule suspension behind the redispersion continues with 20 times of distilled water dilutings or without dilution, with Zetasizer 3000HS analysis-e/or determining particle diameter and surface potential (referring to table 1).
Result of study shows, the direct lyophilization of medicament nano granule suspension, and the particle diameter behind the freeze-dried powder redispersion significantly increases.Add the protective agent poloxamer in the medicament nano granule suspension, along with the decline of suspension Chinese medicine concentration, the particle diameter of medicament nano granule reduces gradually behind the freeze-dried powder redispersion.Therefore, when lyophilization, need to add an amount of freezing drying protective agent poloxamer, the concentration of suspension Chinese medicine is controlled at 5mg/ml and following.
Size ratio is than (g/100ml) before and after the lyophilization of table 1 different pharmaceutical concentration nanoparticle suspension
| Form | Extension rate | Each component in the nanoparticle | Poloxamer | Particle diameter (nm) before the lyophilizing | Redispersion particle diameter (nm) | ||
| Medicine | Lecithin | Poloxamer | |||||
| 1 2 3 4 5 6 7 | 0 0 2 5 10 50 100 | 1.0 1.0 0.5 0.2 0.1 0.02 0.01 | 0.1 0.1 0.05 0.02 0.01 0.002 0.001 | 0.225 0.225 0.1125 0.045 0.0225 0.0045 0.00225 | 0 2.0 2.0 2.0 2.0 2.0 2.0 | 261.3 261.3 261.3 261.3 261.3 261.3 261.3 | 895.6 591.8 489.3 422.5 368.3 306.9 301.4 |
Embodiment two: the freeze-drying preparation of medicament nano granule powder
Get the medicament nano granule suspension that obtains according to application number 200510061371.1 disclosed methods; it is 5mg/mL that adding distil water is diluted to drug level; adding recipe quantity mannitol and polyvinylpyrrolidone K30 respectively dissolves as freeze drying protectant (referring to table 2); place the lyophilizing dish, liquid level is 2～3cm.Put on the flaggy of lyophilization mechanical goods chamber, about 6～7 hours of-45 ℃ of pre-freezes, open water vessel refrigeration switch, finish the back in the pre-freeze insulation and open vacuum pump, when the vacuum reading is reduced to 10 handkerchiefs when following, the goods room temperature that raises gradually is to-5 ℃, be incubated about 24～30 hours, when products temperature and flaggy temperature near the time, continue rising flaggy temperature to about 35 ℃ and be incubated 3 hours, lyophilization is about 34 hours altogether, obtains the Nano medication powder.
Nano medication powder adding distil water is diluted to the preceding same medicine concentration of lyophilizing, hand vibration 1min redispersion.Medicament nano granule suspension behind the redispersion continues with 20 times of distilled water dilutings, with Zetasizer3000HS analysis-e/or determining particle diameter and surface potential (referring to table 2).
Size ratio before and after the lyophilization of table 2 drug level 5mg/mL nanoparticle suspension
| Form | Each component (g/100ml) in the nanoparticle | Freeze drying protectant addition (g/100ml) | Particle diameter (nm) before the lyophilizing | Redispersion particle diameter (nm) | |||
| Medicine | Lecithin | Poloxamer 188 | Mannitol | Polyvinylpyrrolidone k30 | |||
| 1 2 | 0.5 0.5 | 0.05 0.05 | 0.1125 0.1125 | 6.8 3.4 | 2.7 1.4 | 260.9 260.9 | 487.0 457.9 |
Result of study shows, under high drug level condition, adopts recipe quantity mannitol and polyvinylpyrrolidone k30 as freeze drying protectant, and the medicament nano granule particle diameter of redispersion is significantly increased after the freeze-dried powder lyophilizing.
Embodiment three: the freeze-drying preparation of medicament nano granule powder
Get the medicament nano granule suspension that obtains according to application number 200510061371.1 disclosed methods; with distilled water diluting to drug level 2mg/mL; add recipe quantity poloxamer 188 respectively; mannitol and polyvinylpyrrolidone k30 dissolve as freeze drying protectant (referring to table 3); place the lyophilizing dish; liquid level is 2～3cm; put on the flaggy of lyophilization mechanical goods chamber; about 6～7 hours of-45 ℃ of pre-freezes; open water vessel refrigeration switch; finish the back in the pre-freeze insulation and open vacuum pump; reduce to 10 handkerchiefs when following when the vacuum reading, the goods room temperature that raises gradually is incubated about 24～30 hours to-5 ℃; when products temperature and flaggy temperature near the time; continue rising flaggy temperature to about 35 ℃ and be incubated 3 hours, lyophilization is about 34 hours altogether, obtains the Nano medication powder.
Nano medication powder adding distil water is diluted to the preceding same medicine concentration of lyophilizing, hand vibration 1min redispersion.Medicament nano granule suspension behind the redispersion continues with 20 times of distilled water dilutings, with Zetasizer3000HS analysis-e/or determining particle diameter (referring to table 3).
Result of study shows, reducing under the drug level condition, adopts suitable freezing drying protective agent, can obviously improve the particle diameter behind the freeze-dried powder redispersion.
Size ratio before and after the lyophilization of table 3 drug level 2mg/mL nanoparticle suspension
| Form | Each component (g/100ml) in the nanoparticle | Freeze drying protectant addition (g/100ml) | Particle diameter (nm) before spray is done | Redispersion particle diameter (nm) | ||||
| Medicine | Lecithin | Poloxamer 188 | Poloxamer 188 | Mannitol | Polyvinylpyrrolidone k30 | |||
| 1 2 3 4 5 6 | 0.2 0.2 0.2 0.2 0.2 0.2 | 0.02 0.02 0.02 0.02 0.02 0.02 | 0.045 0.045 0.045 0.045 0.045 0.045 | 2.0 2.0 1.0 0 0 0 | 1.2 1.2 1.2 1.2 2.4 5.4 | 2.4 0 1.2 0 0 2.26 | 258.2 258.2 258.2 258.2 258.2 258.2 | 379.1 418.3 431.1 448.4 427.8 315.4 |
Embodiment four: the spray drying method for preparation of medicament nano granule powder
Get the medicament nano granule suspension that obtains according to application number 200510061371.1 disclosed methods; with distilled water diluting or without dilution; add mannitol; dissolving; control spray-dired inlet temperature: 130 ℃, leaving air temp: 85 ℃, material flow: 5ml/min; air velocity 600L/min collects and obtains the Nano medication powder.
Nano medication powder adding distil water is diluted to spray and does preceding same medicine concentration; hand vibration 1min redispersion; medicament nano granule suspension behind the redispersion continues with 20 times of distilled water dilutings or without dilution, with Zetasizer 3000HS analysis-e/or determining particle diameter (referring to table 4).
Result of study shows, the direct spray drying of medicament nano granule suspension, and the particle diameter behind the nanoparticle redispersion significantly increases.Add protective agent mannitol in the medicament nano granule suspension, along with the decline of suspension Chinese medicine concentration, the particle diameter of nanoparticle reduces gradually behind the freeze-dried powder redispersion.When the concentration of medicament nano granule suspension Chinese medicine is controlled at 5mg/ml and following, add spray drying after an amount of protective agent, can obtain the medicament nano granule powder of redispersion particle diameter＜500nm.
Size ratio is than (g/100ml) before and after the table 4 different pharmaceutical concentration nanoparticle suspension spray drying
| Form | Extension rate | Each component in the nanoparticle | Mannitol | Particle diameter (nm) before spray is done | Redispersion particle diameter (nm) | ||
| Medicine | Lecithin | Poloxamer | |||||
| 1 2 3 4 5 | 0 0 2 5 10 | 1.0 1.0 0.5 0.2 0.1 | 0.1 0.1 0.05 0.02 0.01 | 0.225 0.225 0.1125 0.045 0.0225 | 0 2.0 2.0 2.0 2.0 | 265.2 265.2 265.2 265.2 265.2 | 703.7 522.6 465.3 394.7 338.4 |
Embodiment five: the spray drying method for preparation of medicament nano granule powder
Get the medicament nano granule suspension that obtains according to application number 200510061371.1 disclosed methods; it is 5mg/mL that adding distil water is diluted to drug level; add recipe quantity poloxamer 188, mannitol and polyvinylpyrrolidone K30 respectively as the dried protective agent of spray (referring to table 5) dissolving; control spray-dired inlet temperature: 130 ℃; leaving air temp: 85 ℃; material flow: 5ml/min, air velocity 600L/min collects and obtains the Nano medication powder.
Nano medication powder adding distil water is diluted to spray and does preceding same medicine concentration, hand vibration 1min redispersion, and the medicament nano granule suspension behind the redispersion continues with 20 times of distilled water dilutings, with Zetasizer3000HS analysis-e/or determining particle diameter (referring to table 5).
Result of study shows; to prepare the indissoluble medicament nano granule suspension according to the method that number of patent application 200510061371.1 provides, to be diluted to drug level be 5mg/mL; select suitable spray drying protective agent, can significantly improve the particle diameter behind the nanoparticle redispersion.
The different spray drying protective agents of table 5 are to spraying the influence of doing front and back medicament nano granule particle diameter
| Form | Each component (g/100ml) in the nanoparticle | Spray dried protective agent addition (g/100ml) | Particle diameter (nm) before spray is done | Redispersion particle diameter (nm) | ||||
| Medicine | Lecithin | Poloxamer 188 | Poloxamer 188 | Mannitol | Polyvinylpyrrolidone k30 | |||
| 1 2 3 4 5 6 7 | 0.5 0.5 0.5 0.5 0.5 0.5 0.5 | 0.05 0.05 0.05 0.05 0.05 0.05 0.05 | 0.1125 0.1125 0.1125 0.1125 0.1125 0.1125 0.1125 | 0.1 0.1 0.5 0 0 0 0 | 0.15 0.5 0 1.5 3.5 6.5 12.8 | 0.1 0.25 0 0.5 1.5 2.65 5.2 | 254.3 254.3 254.3 254.3 254.3 254.3 254.3 | 687.4 573.1 524.6 491.8 358.7 263.3 281.7 |
Need not further to elaborate, believe and adopt the disclosed content in front, those skilled in the art can use the present invention to greatest extent.Therefore, the embodiment of front is interpreted as only illustrating, but not limits the scope of the invention by any way.
Claims (12)
1, a kind of redispersible nanometer particle of insoluble medicine; it is characterized in that: form by sirolimus nanoparticle and freezing drying protective agent or spray drying protective agent; its weight percentage is a sirolimus nanoparticle 0.6%～100%; freezing drying protective agent 0%～99.3%; spray drying protective agent 0～96.4%; after meeting the water redispersion, its mean diameter is less than 1000nm.
2. a kind of redispersible nanometer particle of insoluble medicine according to claim 1 is characterized in that: after meeting the water redispersion, its mean diameter is less than 500nm.
3. a kind of redispersible nanometer particle of insoluble medicine according to claim 1; it is characterized in that: freezing drying protective agent is selected one or more the mixture in polyvinylpyrrolidone k30, poloxamer, mannitol, sorbitol, lactose, sucrose, glucose, the trehalose for use, and its consumption is 0%～99.3% of a total solid weight.
4. a kind of redispersible nanometer particle of insoluble medicine according to claim 1; it is characterized in that: the spray drying protective agent is selected one or more the mixture in polyvinylpyrrolidone k30, poloxamer, mannitol, sorbitol, lactose, sucrose, glucose, the trehalose for use, and its consumption is 0～96.4% of a total solid weight.
5. according to claim 1 or 3 described a kind of redispersible nanometer particle of insoluble medicine; it is characterized in that: the freezing drying protective agent weight percent consists of poloxamer 188 0%～99.3%; mannitol 0%～90.0%, polyvinylpyrrolidone k30 0%～40.9%.
6. according to claim 1 or 4 described a kind of redispersible nanometer particle of insoluble medicine; it is characterized in that: the spray drying protective agent consists of poloxamer 188 0%～43.0% (w/w); mannitol 0%～93.8% (w/w), polyvinylpyrrolidone k30 0%～27.9% (w/w).
7. the preparation method of a kind of redispersible nanometer particle of insoluble medicine according to claim 1 is characterized in that the freeze-drying method preparation realizes by following steps:
The thing nanoparticle suspension of getting it filled; according to the preparation requirement; add freezing drying protective agent; dissolving; place the lyophilizing dish, liquid level is 2～3cm, puts on the flaggy of lyophilization mechanical goods chamber; about 6～7 hours of-45 ℃ of pre-freezes; open water vessel refrigeration switch, finish the back in the pre-freeze insulation and open vacuum pump, when the vacuum reading is reduced to 10 handkerchiefs when following; the goods room temperature that raises gradually is to-5 ℃; be incubated about 24～30 hours, when products temperature and flaggy temperature near the time, continue rising flaggy temperature to about 35 ℃ and be incubated 3 hours; lyophilization is about 34 hours altogether, obtains the Nano medication powder.
8. the preparation method of a kind of redispersible nanometer particle of insoluble medicine according to claim 1 is characterized in that the spray drying process preparation realizes by following steps:
The thing nanoparticle suspension of getting it filled adds the dissolving of spray drying protective agent respectively, controls spray-dired inlet temperature: 130 ℃, and leaving air temp: 85 ℃, material flow: 5ml/min, air velocity 600L/min collects and obtains the Nano medication powder.
9. the preparation method of a kind of redispersible nanometer particle of insoluble medicine according to claim 7 is characterized in that: through the medicament nano granule powder that freeze-drying prepares, redispersion forms medicament nano granule in distilled water.
10. the preparation method of a kind of redispersible nanometer particle of insoluble medicine according to claim 8 is characterized in that: the medicament nano granule powder that spray-dried method prepares, redispersion forms medicament nano granule in distilled water.
11. according to claim 1 or the arbitrary described a kind of redispersible nanometer particle of insoluble medicine of 7-8, it is characterized in that: described medicament nano granule powder is used in preparation Nano medication solid preparation.
12. a kind of redispersible nanometer particle of insoluble medicine according to claim 11 is characterized in that: dosage form is tablet, capsule, granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510061510 CN1771911B (en) | 2005-11-10 | 2005-11-10 | Re-dispersible nanometer particle of insoluble medicine and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510061510 CN1771911B (en) | 2005-11-10 | 2005-11-10 | Re-dispersible nanometer particle of insoluble medicine and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1771911A true CN1771911A (en) | 2006-05-17 |
| CN1771911B CN1771911B (en) | 2010-05-12 |
Family
ID=36759166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510061510 Active CN1771911B (en) | 2005-11-10 | 2005-11-10 | Re-dispersible nanometer particle of insoluble medicine and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1771911B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100427584C (en) * | 2006-08-11 | 2008-10-22 | 江南大学 | Plant lactobacillus and method of biological preparing conjugated linoleic acid using the same |
| CN107049963A (en) * | 2017-06-23 | 2017-08-18 | 北京化工大学 | A kind of sirolimus Nano medication composition and preparation method thereof |
| CN114869852A (en) * | 2021-12-28 | 2022-08-09 | 青岛润达生物科技有限公司 | Preparation method for improving antioxidant activity of ganoderma lucidum polysaccharide powder and protective agent |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100479807C (en) * | 2002-08-15 | 2009-04-22 | 刘云清 | Medicine conveying system--preparation method of solid nano medicine |
| CN100339067C (en) * | 2003-07-22 | 2007-09-26 | 范敏华 | Nanometer emulsion and preparation method thereof |
| CN1194683C (en) * | 2003-08-29 | 2005-03-30 | 上海医药工业研究院 | Silymarin behenic acid glyceride lipid nano particle oral solution dosage and its preparation method |
| CN1493361A (en) * | 2003-08-29 | 2004-05-05 | 上海医药工业研究院 | Lipid nano-particle of glyceride behenate and its preparation method |
-
2005
- 2005-11-10 CN CN 200510061510 patent/CN1771911B/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100427584C (en) * | 2006-08-11 | 2008-10-22 | 江南大学 | Plant lactobacillus and method of biological preparing conjugated linoleic acid using the same |
| CN107049963A (en) * | 2017-06-23 | 2017-08-18 | 北京化工大学 | A kind of sirolimus Nano medication composition and preparation method thereof |
| CN107049963B (en) * | 2017-06-23 | 2020-11-03 | 北京化工大学 | Sirolimus nano-drug composition and preparation method thereof |
| CN114869852A (en) * | 2021-12-28 | 2022-08-09 | 青岛润达生物科技有限公司 | Preparation method for improving antioxidant activity of ganoderma lucidum polysaccharide powder and protective agent |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1771911B (en) | 2010-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhao et al. | Long-term storage of lipid-like nanoparticles for mRNA delivery | |
| Yu et al. | Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: spray drying versus spray freeze drying preparation | |
| Kumar et al. | Ketoconazole encapsulated in chitosan-gellan gum nanocomplexes exhibits prolonged antifungal activity | |
| Valizadeh et al. | Antibacterial activity of clarithromycin loaded PLGA nanoparticles | |
| CN102274190B (en) | Paclitaxel alhumin submicron for injection and preparation method thereof | |
| Dadashi et al. | Preparation, characterization, and antibacterial effect of doxycycline loaded kefiran nanofibers | |
| Zhang et al. | PEI-modified macrophage cell membrane-coated PLGA nanoparticles encapsulating Dendrobium polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses | |
| CN103330680A (en) | Nano drug transdermal preparation and preparation method thereof | |
| Yang et al. | Design and evaluation of inhalable chitosan-modified poly (DL-lactic-co-glycolic acid) nanocomposite particles | |
| Tan et al. | A novel bottom-up process to produce nanoparticles containing protein and peptide for suspension in hydrofluoroalkane propellants | |
| CN102727899A (en) | Protein-medicament-carrying PLGA composite microspheres and preparation method thereof | |
| Shiehzadeh et al. | Dry powder form of polymeric nanoparticles for pulmonary drug delivery | |
| Alamdaran et al. | In-vitro study of the novel nanocarrier of chitosan-based nanoparticles conjugated HIV-1 P24 protein-derived peptides | |
| Durán et al. | Microencapsulation of antibiotic rifampicin in poly (3-hydroxybutyrate-co-3-hydroxyvalerate) | |
| CN1771911A (en) | Re-dispersible nanometer particle of insoluble medicine and its prepn | |
| Yuan et al. | Preparation and characterization of recombinant human growth hormone–Zn2+-dextran nanoparticles using aqueous phase–aqueous phase emulsion | |
| WO2012103802A1 (en) | Liquid medicinal composition containing echinocandin antifungal agent micafungin | |
| CN101721375B (en) | Insulin slow release micron sphere composition and preparation method thereof | |
| WO2018196819A1 (en) | Protein particle wrapped with medicine insoluble in water and preparation method therefor | |
| Liu et al. | Composite inclusion complexes containing sodium alginate composite nanogels for pH-responsive valnemulin hydrochloride release | |
| CN104288093A (en) | Application of nano-drug transdermal preparation in tumors | |
| Ashvini et al. | Clarithromycin-loaded Chitosan Nanoparticles: Preparation, Characterisation and Antibacterial Activity on Streptococcus pneumonia. | |
| Sharma et al. | Formulation and physicochemical evaluation of nanostructured lipid carrier for codelivery of clotrimazole and ciprofloxacin | |
| CN108309943B (en) | Compound preparation based on medicine particles | |
| Fu et al. | Therapeutic effects of paclitaxel loaded polyethylene glycol-polylactic acid-glycolic acid copolymer nanoparticles on pancreatic cancer in rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |